Experimental Autoimmune Encephalomyelitis (EAE) Model Development Service

Experimental Autoimmune Encephalomyelitis (EAE) Models, Accelerate Your Neurological Drug Discovery! Are you currently facing long drug development cycles, challenges in validating therapeutic targets, or difficulty in translating preclinical findings to clinical success? Our EAE models service helps you accelerate drug discovery, validate novel targets, and streamline preclinical development through advanced EAE model induction, comprehensive assessment, and expert analysis.

EAE is the gold-standard animal model for Multiple Sclerosis (MS), a debilitating autoimmune disease of the central nervous system (CNS). EAE faithfully mimics key pathological features of MS, including neuroinflammation, immune cell infiltration, demyelination, and axonal damage. This model is indispensable for dissecting disease mechanisms, identifying therapeutic targets, and evaluating the efficacy of potential drug candidates, providing a crucial bridge from basic research to clinical application.

How Our EAE Models Can Assist Your Project

Creative Biolabs' EAE models service provides critical solutions for your neuroinflammation and MS research. We deliver precise identification of effective therapeutic candidates, elucidation of drug mechanisms of action, validation of novel biomarkers, and robust preclinical data packages essential for regulatory submissions. Our expertise ensures your project gains clear, actionable insights, propelling your drug development forward with confidence.

Discover How We Can Help - Request a Consultation

Workflow:

Our workflow is designed for clarity, efficiency, and comprehensive data generation, ensuring a seamless experience for your project.

• Required Starting Materials:

To initiate your EAE study, we typically require:

1. Compound Information: Detailed structure, purity, formulation, and stability data for your therapeutic agent.
2. Specific Research Questions: Clearly defined hypotheses and objectives for the study, including desired therapeutic outcomes.
3. Targeted Pathways/Mechanisms: Any known or hypothesized biological pathways or mechanisms of action relevant to your compound.

• Final Deliverables:

Upon completion of the service, you will receive:

1. Comprehensive Study Report: A detailed document including raw data, analyzed results, statistical interpretations, and expert conclusions.
2. High-Resolution Histopathological Images: Annotated images and quantitative data for all assessed CNS pathology.
3. Immunological and Biochemical Profiling Data: Complete datasets from flow cytometry, ELISA, and NfL measurements, with accompanying analysis.

• Estimated Timeframe:

The typical timeframe for EAE studies ranges from 8 to 16 weeks, depending on the model complexity, the number of cohorts, and the desired comprehensive readouts.

Why Choose Us?

Choosing CBL for your EAE model studies means partnering with a leader in preclinical neuroinflammation research. Our two decades of specialized expertise, combined with state-of-the-art facilities and a client-centric approach, uniquely position us to accelerate your drug discovery efforts. We offer unparalleled scientific acumen, customized study designs tailored to your specific needs, and comprehensive end-to-end solutions from model induction to advanced data analysis. Our GLP-compliant facilities ensure the highest quality and reproducibility of your data, leading to actionable insights and accelerated timelines for your therapeutic candidates.

Experience the CBL Advantage - Get a Quote Today

EAE Models

EAE is typically induced in genetically susceptible animals (most commonly mice and rats) through immunization with myelin antigens (e.g., myelin oligodendrocyte glycoprotein [MOG], including specific fragments like MOG (35-55) or MOG (1-125), proteolipid protein [PLP], or myelin basic protein [MBP]) emulsified in complete Freund's adjuvant (CFA), often supplemented with pertussis toxin. This immunization triggers an autoimmune response mediated primarily by autoreactive T cells, leading to inflammation and demyelination in the brain and spinal cord.

Fig.1 Gene expression of Tnfα and Ifng in EAE.

Customer Reviews

"Enhanced Efficacy Screening. Using CBL's EAE Models in our research has significantly improved our ability to screen novel immunomodulators for MS. Their detailed clinical scoring and histological analysis provided clear efficacy readouts, streamlining our lead optimization." - Dr. Jne Sth, 2024

"In-depth Mechanism Elucidation. CBL's comprehensive immunological profiling within the EAE model facilitated a deep understanding of our compound's mechanism of action, which was critical for our target validation efforts. Their expertise is unmatched." - Dr. Mrk Dvis, 2023

"Valuable Translational Biomarkers. The inclusion of neurofilament light chain analysis in CBL's EAE studies provided invaluable translational biomarker data, helping us predict clinical relevance and design our early-phase trials more effectively. A truly collaborative experience." - Dr. Ana Kur, 2024

What We Can Offer

At CBL, our commitment to excellence in EAE models translates into tangible advantages for your research:

• One-Stop EAE Service: We provide comprehensive, integrated EAE study solutions, managing your project seamlessly from initial consultation and customized study design through model induction, extensive data collection, and final expert analysis.
• Optimized Process Development: Benefit from our efficient upstream and downstream EAE model development protocols, ensuring consistent disease induction, reliable progression, and robust experimental outcomes.
• High-Throughput Capabilities: Our infrastructure supports the capacity for high-throughput compound screening within various EAE models, accelerating your lead identification and optimization phases.
• Robust Quality System: We operate under a well-established quality system, incorporating principles of Quality-by-Design (QbD) and utilizing advanced process analytical techniques (PAT) where applicable, to guarantee the integrity and reproducibility of your EAE study data.
• Meticulous Animal Care & Procedures: Our strict adherence to ethical guidelines and meticulous standardized experimental procedures minimize variability and ensure the highest standards of animal welfare throughout the EAE study process.
• Preclinical Data for Regulatory Pathways: Our EAE production and data generation meet rigorous preclinical standards, producing robust datasets suitable for informing and supporting your regulatory submissions.
• Commitment to Ethical Research: Beyond compliance, we are deeply invested in ethical animal welfare measures and continually refine our practices to ensure responsible and humane research.
• Exceptional Documentation: Our stringent quality assurance ensures documentation of strain origins and assessment procedures are meticulously maintained and approved, providing full transparency and traceability for your EAE study.
• Guaranteed Model Stability: We guarantee the stability and consistent characterization of our EAE models and animal strains through rigorous monitoring and management of our vivarium and breeding programs.
• Tailored Study Optimization: We specialize in optimizing culture conditions and model parameters to maximize therapeutic yield and translational relevance, customizing EAE study conditions to fit your unique compound and research goals.
• Flexible Study Execution: We can run your EAE study in various modes, offering flexible dosing paradigms including prophylactic, interventional, or therapeutic approaches to best address your compound's profile.
• High-Standard Quality Control: Utilizing advanced quality control tools, we precisely quantify and evaluate the quality of products (e.g., myelin antigens used for induction) and the resulting biological data from our EAE studies.

Related Services

To further support your neurological drug discovery programs, CBL offers a suite of complementary services:

• Neuroinflammation Assays: Explore our advanced in vitro and ex vivo assays to investigate specific inflammatory pathways and cellular responses relevant to CNS disorders.
• Neurodegenerative Disease Models: Beyond EAE, we provide a range of models for other neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, and ALS, to support diverse research needs.
• Biomarker Discovery & Validation: Our expertise extends to identifying and validating novel biomarkers that can be translated from preclinical models to clinical trials.

Ready to advance your neurological drug discovery project? Our team of specialists is eager to discuss your specific needs and how our EAE model expertise can empower your next breakthrough.

Contact Our Team for More Information and to Discuss Your Project.